Cybin is trading at $7.15 (9.8%) up in pre-market following bullish analyst coverage and commentary regarding its reinforced balance sheet.
- Analysts highlighted significant clinical progress in the company's psychedelic programs alongside a strengthened cash position.
- The improved financial outlook is driving renewed investor interest and supporting sentiment following the prior session's pullback.